Facts and Figures
2010 FINANCIAL HIGHLIGHTS
-
Total revenues of £100.2m (2009: £79.0m)
• Continued strong European performance
• Partnering income of £13.4m including £8.1m milestone payment on US approval of Fortesta (2009: £5.2m) -
EBITDA of £10.8m (2009: £5.1m loss)
-
Operating profit of £6.1m (2009: £9.6m loss)
-
Pre-tax loss reduced to £0.6m (2009: £15.0m)
-
Closing cash position of £19.4m (31 December 2009: £19.0m)
2010 OPERATING HIGHLIGHTS
-
Continued European growth
-
European revenues up 21% to £80.0m
-
Abstral a key driver of growth
-
Adcal-D3 sales up 14% to £23.2m
-
US business experienced challenges and successes
-
Sancuso sales of £6.8m despite manufacturing interruption
-
Fortesta approved by FDA
-
Abstral approved by FDA in early January 2011
-
Worldwide partnering programme made a significant contribution
-
Partnering product sales revenues of £2.4m
-
Fortesta FDA approval triggered £8.1m ($12.5m) milestone payment (cash received January 2011)
-
13 approvals and 5 new product country launches through partners
-
Refinancing of the Group’s borrowing facility in January 2011
-
New strategic relationship with Paladin Labs Inc. announced
SHARE PRICE
